Noninvasive biomarkers of liver status, such as PRO-C3 for Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), which specifically target the dynamics of liver fibrosis, provide a novel tool to determine a patient's disease progression.
Such liver disease biomarkers could be used for risk stratification of patients as well as prognostic enrichment of clinical trials targeting the neediest and highest risk patients, thereby increasing the likelihood of success.
